Background and Objectives Th17 cells represent a subset of T helper lymphocytes that produces several inflammatory cytokines, including interleukin-17A, -17F, -21, -22, and tumor necrosis factor. Increased Th17 cell differentiation and IL-17 production have been observed in rheumatoid arthritis (RA) and in several other autoimmune diseases. IL-17 contributes to development of inflammation and promotes osteoclast differentiation in RA. We have studied the differentiation of Th17 cells.
Materials and Methods CD4 positive T cells were negatively separated by magnetic method from peripheral blood mononuclear cells (PBMC) of healthy volunteers. The cells were treated for 5-10 days with anti-CD3 and anti-CD28 antibodies and with TGFβ (2.5ng/ml), IL-6 (25ng/ml) and IL-1 (10ng/ml) cytokines, furthermore with anti-IL-4 (10μg/ml) and anti-IFNγ (10μg/ml) blocking antibodies. The IL-17 and IL-22 production was measured by ELISPOT and ELISA, the RORγt expression was measured by real-time PCR and by Western blot methods, cell viability was monitored by Trypan blue staining and by Annexin V binding.
Results Anti-CD3/CD28 treatment increased the IL-17 production, but did not alter the RORγt expression. The anti-CD3/CD28, TGFβ, IL-6, and IL-1 induced RORγt expression was further increased by the anti-IL-4 and anti-IFNγ antibody treatment. Anti-CD3/CD28-induced IL-22 production was inhibited by TGFβ, IL-6, IL-1, anti-IL-4 and anti-IFNγ antibody treatment. The applied treatments did not change the viability of the cells.
Conclusion Our present results suggest that IL-17 and IL-22 production are differentially regulated during CD4 T cell activation and Th17 differentiation.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.